Hemodynamic alterations in idiopathic hypertrophic subaortic stenosis induced by sympathomimetic drugs∗

doi:10.1016/0002-9149(62)90373-9

The American Journal of Cardiology

Volume 10, Issue 4, October 1962, Pages 489-495

https://doi.org/10.1016/0002-9149(62)90373-9 Get rights and content

Abstract

The hemodynamic alterations induced by isoproterenol and methoxamine in 7 patients with idiopathic hypertrophic subaortic stenosis are described. The intravenous administration of 2 μg. of isoproterenol generally lowered the cardiac output and the systemic arterial pressure, while elevating the left ventricular systolic and end-diastolic pressures. Thus, this drug consistently decreased the effective orifice within the left ventricular outflow tract. In contrast, the administration of 2 mg. of methoxamine abolished the left ventriculoarterial pressure gradient in 3 patients. Variations in the severity of obstruction dependent upon alterations in intraventricular conduction were also demonstrated. The mechanisms responsible for the observed changes were discussed.

References (16)

E. Braunwald et al.
Idiopathic hypertrophic subaortic stenosis: clinical, hemodynamic, and angiographic manifestations
Am. J. Med.
(1960)
H.T. Dodge et al.
Cardiovascular effects of isoproterenol in normal subjects and subjects with congestive heart failure
Am. Heart J.
(1960)
R. Gorlin et al.
Hydraulic formula for calculation of area of stenotic mitral valve, other cardiac valves, and central circulatory shunts
Am. Heart J.
(1951)
E. Braunwald et al.
Editorial. Hypertrophic subaortic stenosis—a broadened concept
Circulation
(1962)
A.G. Morrow et al.
Functional aortic stenosis
Circulation
(1959)
J.F. Goodwin et al.
Clinical aspects of cardiomyopathy
Brit. M. J.
(1961)
E.C. Brockenbrough et al.
A hemodynamic technic for the detection of hypertrophic subaortic stenosis
Circulation
(1961)
E. Braunwald et al.
Studies on digitalis, v. A comparison of the effects of ouabain on left ventricular dynamics in valvular aortic stenosis and hypertrophie sub-aortic stenosis
Circulation
(1962)

There are more references available in the full text version of this article.

Cited by (91)

Sudden cardiac death in childhood hypertrophic cardiomyopathy
2023, Disease-a-Month
The most prevalent cause of mortality in children with hypertrophic cardiomyopathy (HCM) is sudden cardiac death (SCD), which happens more frequently than in adult patients. Risk stratification tactics have generally been drawn from adult practice, however emerging data has revealed significant disparities between children and adult cohorts, implying the need for pediatric-specific risk stratification methodologies.
We conducted an all-language literature search on Medline, Cochrane, Embase, and Google Scholar until October 2021. The following search strings and Medical Subject Heading (MeSH) terms were used: “HCM,” “SCD,” “Sudden Cardiac Death,” and “Childhood Onset HCM.” We explored the literature on the risk of SCD in HCM for its epidemiology, pathophysiology, the role of various genes and their influence, associated complications leading to SCD and preventive and treatment modalities.
Childhood-onset HCM is linked to significant life-long morbidity and mortality, including a higher SCD rate in children than in adults. The present focus is on symptom relief and avoiding illness-related consequences, but the prospect of future disease-modifying medicines offers an intriguing opportunity to alter disease expression and outcomes in these young individuals.
Current preventive recommendations promote implantable cardioverter defibrillator placement based on cumulative risk factor thresholds, although they have been demonstrated to have weak discriminating capacity. This article addresses questions and discusses the etiology, risk factors, and method to risk stratification for SCD in children with HCM.
Reflections on Six Decades of Hypertrophic Cardiomyopathy From Eugene Braunwald
2022, American Journal of Cardiology
On October 16 to 18, 2021, the 3-day 7th International Summit of Hypertrophic Cardiomyopathy was held virtually with almost 700 registrants and faculty from 40 countries and 42 states (Drs. Martin and Barry Maron, Directors). This meeting, the largest for this disease, was an opportunity to engage on a wide variety of topics with insights relevant to hypertrophic cardiomyopathy provided by 47 lectures, debates, and comprehensive discussions from 36 distinguished international speakers, including Dr. Eugene Braunwald.
Effects of Metoprolol on Exercise Hemodynamics in Patients With Obstructive Hypertrophic Cardiomyopathy
2022, Journal of the American College of Cardiology
The relationship between exercise hemodynamics, loading conditions, and medical treatment in patients with obstructive hypertrophic cardiomyopathy (HCM) is incompletely understood.
This study aimed to investigate the effect of metoprolol on invasive hemodynamic parameters at rest and during exercise in patients with obstructive HCM.
This randomized, double-blind, placebo-controlled crossover trial enrolled 28 patients with obstructive HCM and New York Heart Association functional class ≥II. Patients were randomized to initiate either metoprolol 150 mg or placebo for 2 consecutive 2-week periods. Right-heart catheterization and echocardiography were performed at rest and during exercise at the end of each treatment period. The primary outcome was the difference in pulmonary capillary wedge pressure (ΔPCWP) between peak exercise and rest.
No treatment effect on ΔPCWP was observed between metoprolol and placebo treatment (21 ± 9 mm Hg vs 23 ± 9 mm Hg; P = 0.12). At rest, metoprolol lowered heart rate (P < 0.0001), left ventricular outflow tract (LVOT) gradient (P = 0.01), and increased left ventricular end-diastolic volume (P = 0.02) and stroke volume (SV) (+6.4; 95% CI: 0.02-17.7; P = 0.049). During peak exercise, metoprolol was associated with a lower heart rate (P < 0.0001), a lower LVOT gradient (P = 0.0005), lesser degree of mitral regurgitation (P = 0.004), and increased SV (+9 mL; 95% CI: 2-15 mL; P = 0.008).
In patients with obstructive HCM, exercise was associated with an abnormal rise in PCWP, which was unaffected by metoprolol. However, metoprolol increased SV at rest and peak exercise following changes in end-diastolic volume, LVOT gradient, and degree of mitral regurgitation. (The Effect of Metoprolol in Patients With Hypertrophic Obstructive Cardiomyopathy [TEMPO]; NCT03532802)
Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic Cardiomyopathy
2021, Journal of the American College of Cardiology
The use of β-adrenergic receptor blocking agents in symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM) rests on clinical experience and observational cohort studies.
This study aimed to investigate the effects of metoprolol on left ventricular outflow tract (LVOT) obstruction, symptoms, and exercise capacity in patients with obstructive HCM.
This double-blind, placebo-controlled, randomized crossover trial enrolled 29 patients with obstructive HCM and New York Heart Association (NYHA) functional class II or higher symptoms from May 2018 to September 2020. Patients received metoprolol or placebo for 2 consecutive 2-week periods in random order. The effect parameters were LVOT gradients, NYHA functional class, Canadian Cardiovascular Society (CCS) angina class, Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OSS), and cardiopulmonary exercise testing.
Compared with placebo, the LVOT gradient during metoprolol was lower at rest (25 mm Hg [interquartile range (IQR): 15-58 mm Hg] vs 72 mm Hg [IQR: 28-87 mm Hg]; P = 0.007), at peak exercise (28 mm Hg [IQR: 18-40 mm Hg] vs 62 mm Hg [IQR: 31-113 mm Hg]; P < 0.001), and postexercise (45 mm Hg [IQR: 24-100 mm Hg] vs 115 mm Hg [IQR: 55-171 mm Hg]; P < 0.0001). During metoprolol treatment, 14% of patients were in NYHA functional class III or higher compared with 38% of patients receiving placebo (P < 0.01). Similarly, no patients were in CCS class III or higher during metoprolol treatment compared with 10% during placebo treatment (P < 0.01). These findings were confirmed by higher KCCQ-OSS during metoprolol treatment (76.2 ± 16.2 vs 73.8 ± 19.5; P = 0.039). Measures of exercise capacity, peak oxygen consumption, and N-terminal pro–B-type natriuretic peptide did not differ between the study arms.
Compared with placebo, metoprolol reduced LVOT obstruction at rest and during exercise, provided symptom relief, and improved quality of life in patients with obstructive HCM. Maximum exercise capacity remained unchanged. (The Effect of Metoprolol in Patients with Hypertrophic Obstructive Cardiomyopathy [TEMPO]; NCT03532802)
2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
2021, Journal of Thoracic and Cardiovascular Surgery
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
2020, Journal of the American College of Cardiology
This executive summary of the hypertrophic cardiomyopathy clinical practice guideline provides recommendations and algorithms for clinicians to diagnose and manage hypertrophic cardiomyopathy in adult and pediatric patients as well as supporting documentation to encourage their use.
A comprehensive literature search was conducted from January 1, 2010, to April 30, 2020, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Collaboration, Agency for Healthcare Research and Quality reports, and other relevant databases.
Many recommendations from the earlier hypertrophic cardiomyopathy guidelines have been updated with new evidence or a better understanding of earlier evidence. This summary operationalizes the recommendations from the full guideline and presents a combination of diagnostic work-up, genetic and family screening, risk stratification approaches, lifestyle modifications, surgical and catheter interventions, and medications that constitute components of guideline directed medical therapy. For both guideline-directed medical therapy and other recommended drug treatment regimens, the reader is advised to follow dosing, contraindications and drug-drug interactions based on product insert materials.

View all citing articles on Scopus

View full text

Clinical studyHemodynamic alterations in idiopathic hypertrophic subaortic stenosis induced by sympathomimetic drugs∗

Abstract

Am. J. Med.

Am. Heart J.

Am. Heart J.

Editorial. Hypertrophic subaortic stenosis—a broadened concept

Circulation

Functional aortic stenosis

Circulation

Clinical aspects of cardiomyopathy

Brit. M. J.

A hemodynamic technic for the detection of hypertrophic subaortic stenosis

Circulation

Studies on digitalis, v. A comparison of the effects of ouabain on left ventricular dynamics in valvular aortic stenosis and hypertrophie sub-aortic stenosis

Circulation

Clinical study
Hemodynamic alterations in idiopathic hypertrophic subaortic stenosis induced by sympathomimetic drugs^∗